Advertisement

Advertisement

ESMO Congress 2024

hepatobiliary cancer

Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma

Maeve Lowery, MD, discusses the results of the phase II DUBHE-H-308 trial, which evaluated QL1706—a bifunctional antibody consisting of iparomlimab and tuvonralimab—plus bevacizumab and/or chemotherap...

Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib

Rachna T. Shroff, MD, MS, FASCO, was the discussant for a phase III trial presented at the ESMO Congress 2024 evaluating the efficacy and safety of anlotinib plus penpulimab vs sorafenib as first-line...

hepatobiliary cancer

Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma

Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further abo...

hepatobiliary cancer

Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE

Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Pre...

hepatobiliary cancer

Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma

In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how ...

hepatobiliary cancer

Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial

Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from ...

Advertisement

Advertisement




Advertisement